Rosenblum Silverman Sutton’s DexCom DXCM Stock Holding History

Rosenblum Silverman Sutton’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-115,664	Closed	-$1.66M	–	64
2017 Q4	$1.66M	Sell	115,664 -161,940	-58%	-$2.1M	0.6%	46
2017 Q3	$3.4M	Sell	277,604 -740	-0.3%	-$13.1K	1.29%	27
2017 Q2	$5.09M	Buy	278,344 +246,820	+783%	+$4.56M	2.03%	19
2017 Q1	$668K	Sell	31,524 -3,000	-9%	-$58.6K	0.28%	56
2016 Q4	$515K	Sell	34,524 -200	-0.6%	-$3.54K	0.24%	52
2016 Q3	$761K	Buy	34,724 +644	+2%	+$14.3K	0.35%	53
2016 Q2	$676K	Buy	+34,080	New	+$580K	0.32%	51
2015 Q4	$721K	Hold	35,200	–	–	0.33%	52
2015 Q3	$756K	Sell	35,200 -320	-0.9%	-$7.14K	0.36%	55
2015 Q2	$710K	Buy	+35,520	New	+$624K	0.28%	58
2014 Q4	$487K	Hold	35,400	–	–	0.21%	61
2014 Q3	$354K	Hold	35,400	–	–	0.16%	66
2014 Q2	$351K	Sell	35,400 -800	-2%	-$7.09K	0.16%	61
2014 Q1	$374K	Buy	36,200 +800	+2%	+$8.27K	0.18%	65
2013 Q4	$313K	Buy	+35,400	New	+$280K	0.15%	69

Other funds holding DXCM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Rosenblum Silverman Sutton's DXCM Position: Q1 2018 in Review

Rosenblum Silverman Sutton sold out of DexCom (DXCM) in Q1 2018, closing a stake of 115,664 shares — an estimated $1.66M sold.

Rosenblum Silverman Sutton first reported a position in DXCM in Q4 2013 and held it in 15 quarters. The position peaked at $5.09M in Q2 2017. 276 funds tracked by Wall St. Rank hold DXCM as of Q1 2018.

Rosenblum Silverman Sutton reported no remaining DexCom position as of Q1 2018 after selling out during the quarter.
Rosenblum Silverman Sutton sold 115,664 DexCom shares in Q1 2018, an estimated $1.66M.
Rosenblum Silverman Sutton first reported a position in DexCom in Q4 2013 and held it in 15 quarters.
Rosenblum Silverman Sutton's DexCom position peaked at $5.09M in Q2 2017.
276 funds tracked by Wall St. Rank held DexCom as of Q1 2018.

Based on Rosenblum Silverman Sutton's 13F filing for Q1 2018, filed 10 May 2018.